{"id":"1ad79a73-3d0e-5bb7-b75c-452f2d54ed14","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-rat-dasatinib","predicate":"increases_in_recorded_comparison","statement":"Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"e9a88863-592c-56ac-bb72-8a332e86d286","mechanism_event_label":"Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"88135948-2929-586d-9c29-02e9312b99e3","slug":"dasatinib","display_name":"Dasatinib","entity_type_key":"drug"},"evidence_count":1,"mechanism_event":{"id":"e9a88863-592c-56ac-bb72-8a332e86d286","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-rat-dasatinib-event","event_type":"experimental_observation","label":"Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.","description":"### api-rat-dasatinib\n\nApigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.\nThe abstract and Results describe pretreatment; regimen wording is imperfect in one Methods sentence. Rat exposure does not determine the human interaction magnitude.\nModel and exposure: n=6/group; reported 40 mg/kg/day oral apigenin pretreatment for 7 days; dasatinib 25 mg/kg on day 7.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin pretreatment plus dasatinib","sequence_order":0,"notes":""},{"entity":{"id":"88135948-2929-586d-9c29-02e9312b99e3","slug":"dasatinib","display_name":"Dasatinib","entity_type_key":"drug"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"Apigenin pretreatment plus dasatinib","comparator":"Dasatinib alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"oral partner drug","comparator":"Dasatinib alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"dasatinib","display_name":"Dasatinib","entity_type_key":"drug"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin pretreatment plus dasatinib\", \"comparator\": \"Dasatinib alone\", \"endpoint\": \"Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.\", \"effect_direction\": \"increase\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"apigenin\", \"state\": \"Apigenin pretreatment plus dasatinib\"}, {\"entity_slug\": \"dasatinib\", \"state\": \"oral partner drug\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"n=6/group; reported 40 mg/kg/day oral apigenin pretreatment for 7 days; dasatinib 25 mg/kg on day 7.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-rat-dasatinib; The abstract and Results describe pretreatment; regimen wording is imperfect in one Methods sentence. Rat exposure does not determine the human interaction magnitude.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a7a7af49-96e8-58d6-b1bc-5173ec86602b","evidence_kind":"source_excerpt","locator":"Lines 872-878","start_line":872,"end_line":878,"excerpt":"### api-rat-dasatinib\n\nApigenin pretreatment increased oral dasatinib Cmax by about 94.6% and AUC0–t by about 80.2% in rats.\nThe abstract and Results describe pretreatment; regimen wording is imperfect in one Methods sentence. Rat exposure does not determine the human interaction magnitude.\nModel and exposure: n=6/group; reported 40 mg/kg/day oral apigenin pretreatment for 7 days; dasatinib 25 mg/kg on day 7.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. | 2023 | https://pubmed.ncbi.nlm.nih.gov/36838589/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9964503/ | https://doi.org/10.3390/molecules28041602 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"n=6/group; reported 40 mg/kg/day oral apigenin pretreatment for 7 days; dasatinib 25 mg/kg on day 7.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}